X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3832) 3832
Publication (383) 383
Book Review (137) 137
Book Chapter (39) 39
Newspaper Article (15) 15
Book / eBook (9) 9
Conference Proceeding (7) 7
Newsletter (6) 6
Magazine Article (5) 5
Reference (3) 3
Data Set (1) 1
Dissertation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2561) 2561
index medicus (2014) 2014
animals (1371) 1371
male (1323) 1323
female (1037) 1037
pharmacology & pharmacy (787) 787
middle aged (670) 670
hypertension (602) 602
sodium (560) 560
aged (547) 547
rats (536) 536
adult (521) 521
hypertension - drug therapy (472) 472
cardiac & cardiovascular systems (449) 449
neurosciences (437) 437
risk factors (372) 372
treatment outcome (370) 370
clinical neurology (351) 351
dose-response relationship, drug (351) 351
analysis (339) 339
antihypertensive agents - therapeutic use (330) 330
blood-pressure (330) 330
medicine & public health (315) 315
blood pressure (310) 310
double-blind (308) 308
calcium channel blockers - therapeutic use (290) 290
care and treatment (287) 287
blood pressure - drug effects (286) 286
diuretics (286) 286
drug therapy (274) 274
peripheral vascular disease (269) 269
mice (251) 251
drug therapy, combination (250) 250
mortality (250) 250
hypertension - physiopathology (249) 249
medicine, general & internal (242) 242
research (236) 236
epilepsy (235) 235
drugs (233) 233
health aspects (230) 230
time factors (229) 229
sodium channel blockers - pharmacology (226) 226
article (222) 222
heart failure (209) 209
rats, sprague-dawley (209) 209
sodium chloride symporter inhibitors - therapeutic use (209) 209
disease models, animal (204) 204
heart (201) 201
neurology (199) 199
physiology (197) 197
sodium channels (196) 196
urology & nephrology (194) 194
internal medicine (193) 193
toxicology (188) 188
electrocardiography (187) 187
pain (187) 187
cardiology (183) 183
double-blind method (181) 181
sodium channel blockers - therapeutic use (175) 175
rodents (172) 172
diabetes (169) 169
calcium (167) 167
aged, 80 and over (166) 166
anticonvulsants - therapeutic use (165) 165
sodium - metabolism (163) 163
sodium channels - metabolism (160) 160
therapy (157) 157
pharmacology (156) 156
prevention (156) 156
potassium (154) 154
angiotensin-converting enzyme inhibitors - therapeutic use (153) 153
neurons (149) 149
antiepileptic drugs (147) 147
arrhythmia (146) 146
seizures (144) 144
adolescent (143) 143
clinical trials (143) 143
physiological aspects (143) 143
sodium channel blockers - adverse effects (143) 143
abridged index medicus (142) 142
neuropathic pain (142) 142
risk (142) 142
adrenergic beta-antagonists - therapeutic use (141) 141
review (141) 141
biochemistry & molecular biology (140) 140
drug interactions (137) 137
medical research (137) 137
antihypertensive agents - adverse effects (131) 131
sodium channels - drug effects (131) 131
calcium channel blockers - adverse effects (130) 130
efficacy (130) 130
medicine (130) 130
cardiovascular (129) 129
hypertension - complications (128) 128
ion channels (128) 128
sodium chloride symporter inhibitors - adverse effects (128) 128
dosage and administration (127) 127
endocrinology & metabolism (127) 127
randomized controlled trials as topic (127) 127
management (124) 124
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3839) 3839
German (20) 20
Japanese (11) 11
French (9) 9
Russian (7) 7
Spanish (7) 7
Hungarian (2) 2
Italian (2) 2
Swedish (2) 2
Czech (1) 1
Dutch (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 11/2014, Volume 96, Issue 5, pp. 549 - 558
Journal Article
The Lancet, ISSN 0140-6736, 09/2005, Volume 366, Issue 9489, pp. 895 - 906
The apparent shortfall in prevention of coronary heart disease (CHD) noted in early hypertension trials has been attributed to disadvantages of the diuretics... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | MANAGEMENT | MORBIDITY | DISEASE | GUIDELINES | DOUBLE-BLIND | CALCIUM-ANTAGONISTS | HYPERTENSION | INTERVENTION | Calcium Channel Blockers - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Bendroflumethiazide - administration & dosage | Hypertension - drug therapy | Male | Perindopril - administration & dosage | Sodium Chloride Symporter Inhibitors - administration & dosage | Diuretics | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Blood Pressure - drug effects | Atenolol - administration & dosage | Drug Therapy, Combination | Amlodipine - administration & dosage | Adrenergic beta-Antagonists - administration & dosage | Risk Factors | Amlodipine - adverse effects | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Calcium Channel Blockers - administration & dosage | Atenolol - adverse effects | Hypertension - complications | Aged | Hypertension | Antihypertensive drugs | Evaluation | Dosage and administration | Drug therapy | Prevention | Drug therapy, Combination | Health aspects | Coronary heart disease | Risk factors | Studies | Drugs | Cardiovascular disease | Medical treatment | Myocardial infarction | Heart attacks | Clinical trials | Family medical history | Blood | Randomization | Motivation | Blood pressure | Heart diseases | Antihypertensive agents | Cerebral infarction | Stroke | Fasting | Mortality | Diabetes mellitus | Health risks | Triglycerides | Metabolism | Risk analysis | Atenolol | Fatal | Patients | Coronary artery disease | Cholesterol | Heart rate | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Potassium | Amlodipine/administration & dosage/adverse effects | Bendroflumethiazide/administration & dosage | Cardiovascular Diseases/prevention & control | Perindopril/administration & dosage | MEDICIN OCH HÄLSOVETENSKAP | Atenolol/administration & dosage/adverse effects | Combination | Antihypertensive Agents/administration & dosage/adverse effects | Angiotensin-Converting Enzyme Inhibitors/administration & dosage | MEDICAL AND HEALTH SCIENCES | Coronary Disease/prevention & control | Drug Therapy | Adrenergic beta-Antagonists/administration & dosage/adverse effects | Blood Pressure/drug effects | Hypertension/complications/drug therapy | Calcium Channel Blockers/administration & dosage/adverse effects | Sodium Chloride Symporter Inhibitors/administration & dosage
Journal Article
Cardiovascular Research, ISSN 0008-6363, 7/2011, Volume 91, Issue 1, pp. 53 - 61
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 09/2012, Volume 56, Issue 9, pp. 4793 - 4799
Journal Article
Toxicological Sciences, ISSN 1096-6080, 03/2017, Volume 156, Issue 1, pp. 25 - 38
Drug-induced proarrhythmia is a major safety issue in drug development. Developing sensitive in vitro assays that can predict drug-induced cardiotoxicity in... 
Drug-induced proarrhythmia | iPSC-CMs | Batch variations | ACTION-POTENTIALS | TORSADES-DE-POINTES | DOFETILIDE | CONTRACTILITY | drug-induced proarrhythmia | PROLONGATION | LONG-QT SYNDROME | VENTRICULAR MYOCYTES | MATURATION | IMPEDANCE | TOXICOLOGY | batch variations | RISK-ASSESSMENT | Arrhythmias, Cardiac - chemically induced | Drug Evaluation, Preclinical - economics | Calcium Channel Blockers - adverse effects | Anti-Arrhythmia Agents - pharmacology | Humans | Potassium Channel Blockers - antagonists & inhibitors | Toxicity Tests, Acute - methods | Potassium Channel Blockers - adverse effects | Arrhythmias, Cardiac - pathology | Shal Potassium Channels - genetics | Kv1.5 Potassium Channel - genetics | Toxicity Tests, Acute - economics | Induced Pluripotent Stem Cells - cytology | Voltage-Gated Sodium Channel Blockers - adverse effects | Potassium Channel Blockers - pharmacology | Induced Pluripotent Stem Cells - metabolism | Arrhythmias, Cardiac - metabolism | Induced Pluripotent Stem Cells - pathology | Cell Line | Drug Evaluation, Preclinical - methods | Reproducibility of Results | Induced Pluripotent Stem Cells - drug effects | Myocytes, Cardiac - cytology | Antioxidants - pharmacology | Calcium Channel Blockers - pharmacology | Gene Expression Regulation - drug effects | Myocytes, Cardiac - pathology | Shal Potassium Channels - metabolism | Calcium Channels, L-Type - genetics | Myocytes, Cardiac - drug effects | Cell Differentiation - drug effects | Kv1.5 Potassium Channel - metabolism | Calcium Channel Blockers - chemistry | Myocytes, Cardiac - metabolism | Voltage-Gated Sodium Channel Blockers - pharmacology | Calcium Channels, L-Type - metabolism | Kinetics | Electrophysiological Phenomena - drug effects
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 02/2016, Volume 99, Issue 2, pp. 214 - 223
Journal Article
The Lancet, ISSN 0140-6736, 06/2004, Volume 363, Issue 9426, pp. 2022 - 2031
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan... 
CALCIUM-CHANNEL BLOCKER | LIPID-LOWERING TREATMENT | RECEPTOR BLOCKER | MEDICINE, GENERAL & INTERNAL | ISOLATED SYSTOLIC HYPERTENSION | CONVERTING-ENZYME-INHIBITOR | DOUBLE-BLIND | ANGIOTENSIN-II | ELECTROCARDIOGRAPHIC IDENTIFICATION | CORONARY-ARTERY-DISEASE | BLOOD-PRESSURE | Calcium Channel Blockers - adverse effects | Valsartan | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Male | Sodium Chloride Symporter Inhibitors - therapeutic use | Angiotensin II Type 1 Receptor Blockers | Endpoint Determination | Diuretics | Female | Blood Pressure - drug effects | Double-Blind Method | Risk Factors | Valine - analogs & derivatives | Amlodipine - adverse effects | Treatment Outcome | Antihypertensive Agents - therapeutic use | Hypertension - physiopathology | Amlodipine - therapeutic use | Antihypertensive Agents - adverse effects | Tetrazoles - therapeutic use | Valine - therapeutic use | Aged | Tetrazoles - adverse effects | Valine - adverse effects | Hydrochlorothiazide - therapeutic use | Hypertension | Medical research | Side effects | Drug therapy | Drugs | Heart attacks | Heart surgery | Angioplasty | Risk | Cardiovascular disease | Blood | Randomization | Measurement techniques | Blood pressure | Heart diseases | Age | Heart failure | Edema | Stroke | Mortality | Medical treatment | Health risks | Angina pectoris | Patients | Coronary artery disease | Morbidity | Hypotheses | Coronary vessels | Diabetes | Cardiovascular diseases | Health risk assessment | Mercury | ACE inhibitors
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2016, Volume 15, Issue 3, pp. 259 - 269
Journal Article